Phase I clinical trial - Hématologie Lymphome non Hodgkinien

LYM1001 (67856633LYM1001)
Hématologie Lymphome non Hodgkinien
Essai clinique fermé
Public cible
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Description de l'essai
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Investigateur principal